Zacks Investment Research announced Galena Biopharma Inc (NASDAQ:GALE), boosting its stock price target to $0.25 today
- Updated: October 16, 2016
Just yesterday Galena Biopharma Inc (NASDAQ:GALE) traded 0.94% higher at $0.29. Galena Biopharma Inc’s 50-day moving average is $0.35 and its 200-day moving average is $0.98. The last stock price is down -71.51% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 2,058,925 shares of GALE traded hands, down from an average trading volume of 4,151,390
In a report released on Tuesday October 11, 2016 Zacks Investment Research increased the stock price target of Galena Biopharma Inc (NASDAQ:GALE) to $0.25 reporting a possible downside of -0.14%.
Recent Performance Chart
Galena Biopharma Inc has 52 week low of $0.26 and a 52 week high of $2.49 and has a market capitalization of $0.
Brief Synopsis On Galena Biopharma Inc (NASDAQ:GALE)
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.